Cargando…

Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis

Background Several randomized clinical trials (RCTs) have shown that dual orexin receptor antagonists (DORAs) are effective in the treatment of chronic insomnia. However, the superiority of one particular DORA over the others remains unclear. Objective To perform a network meta-analysis to evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rocha, Rebeka Bustamante, Bomtempo, Fernanda Ferreira, Nager, Gabriela Borges, Cenci, Giulia Isadora, Telles, João Paulo Mota
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Thieme Revinter Publicações Ltda. 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232020/ https://www.ncbi.nlm.nih.gov/pubmed/37257468 http://dx.doi.org/10.1055/s-0043-1768667

Ejemplares similares

Orexin receptor antagonists as therapeutic agents for insomnia
por: Equihua, Ana C., et al.
Publicado: (2013)

Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
por: Roch, Catherine, et al.
Publicado: (2021)

Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia
por: Sarathi Chakraborty, Dwaipayan, et al.
Publicado: (2023)

Suvorexant: The first orexin receptor antagonist to treat insomnia
por: Dubey, Ashok K., et al.
Publicado: (2015)

Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis
por: Xue, Tao, et al.
Publicado: (2023)

Dual orexin receptor antagonists for insomnia in youth with neurodevelopmental disorders: a case series and review
por: Besterman, Aaron D., et al.
Publicado: (2021)

A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
por: Ziemichód, Wojciech, et al.
Publicado: (2022)

The clinical efficacy of orexin antagonists for primary insomnia- A review of the evidence
por: Vasiliu, O.
Publicado: (2023)

Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant
por: Norman, Jessica L, et al.
Publicado: (2016)

Evidence‐based insomnia treatment strategy using novel orexin antagonists: A review
por: Kishi, Taro, et al.
Publicado: (2021)

Orexin Receptor Competitive Antagonists: A Novel target of the Sedative and hypnotics drugs for the pharmacotherapy of Insomnia
por: Banerjee, Indrajit
Publicado: (2018)

Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant
por: Khazaie, Habibolah, et al.
Publicado: (2022)

Orexin, orexin receptor antagonists and central cardiovascular control
por: Carrive, Pascal
Publicado: (2013)

Kinetic properties of “dual” orexin receptor antagonists at OX(1)R and OX(2)R orexin receptors
por: Callander, Gabrielle E., et al.
Publicado: (2013)

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
por: Berger, Benjamin, et al.
Publicado: (2021)

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist
por: Krause, Andreas, et al.
Publicado: (2022)

Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant
por: Dietrich, Hendrik, et al.
Publicado: (2010)

Effects of the dual orexin receptor antagonist DORA-22 on sleep in 5XFAD mice
por: Duncan, Marilyn J., et al.
Publicado: (2019)

The dual orexin receptor antagonist TCS1102 does not affect reinstatement of nicotine-seeking
por: Khoo, Shaun Yon-Seng, et al.
Publicado: (2017)

Effect of a dual orexin receptor antagonist on Alzheimer's disease: Sleep disorders and cognition
por: Zhou, Mengzhen, et al.
Publicado: (2023)

Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study
por: Uchiyama, Makoto, et al.
Publicado: (2022)

The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System
por: Fragale, Jennifer E., et al.
Publicado: (2021)

Factors Associated with Prescriptions for an Orexin Receptor Antagonist Among Japanese Patients with Insomnia: Analysis of a Nationwide Japanese Claims Database
por: Okuda, Shoki, et al.
Publicado: (2023)

Opportunities and perspectives for developing orexin receptor antagonists
por: Steiner, Michel A., et al.
Publicado: (2014)

Differential sleep-promoting effects of dual orexin receptor antagonists and GABA(A) receptor modulators
por: Gotter, Anthony L, et al.
Publicado: (2014)

Inhibition of ghrelin-induced feeding in rats by pretreatment with a novel dual orexin receptor antagonist
por: So, Mariko, et al.
Publicado: (2017)

Dual orexin receptor antagonist induces changes in core body temperature in rats after exercise
por: Martin, Tristan, et al.
Publicado: (2019)

Orexin dual receptor antagonists, zolpidem, zopiclone, eszopiclone, and cognitive research: A comprehensive dose-response meta-analysis
por: Zhou, Mengzhen, et al.
Publicado: (2023)

The Dual Orexin/Hypocretin Receptor Antagonist, Almorexant, in the Ventral Tegmental Area Attenuates Ethanol Self-Administration
por: Srinivasan, Subhashini, et al.
Publicado: (2012)

The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold
por: Gotter, Anthony L, et al.
Publicado: (2013)

Correction to: Inhibition of ghrelin-induced feeding in rats by pretreatment with a novel dual orexin receptor antagonist
por: So, Mariko, et al.
Publicado: (2019)

Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls
por: Yeoh, Jiann Wei, et al.
Publicado: (2014)

A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia
por: Connor, Kathryn M., et al.
Publicado: (2016)

Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder
por: Lalovic, Bojan, et al.
Publicado: (2020)

Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models
por: Anderson, Rachel I., et al.
Publicado: (2014)

Suvorexant, a Dual Orexin Receptor Antagonist, Protected Seizure through Interaction with GABA(A) and Glutamate Receptors
por: Razavi, Bibi Marjan, et al.
Publicado: (2020)

Author Correction: Dual orexin receptor antagonist induces changes in core body temperature in rats after exercise
por: Martin, Tristan, et al.
Publicado: (2020)

Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users
por: Landry, Ishani, et al.
Publicado: (2022)

Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users
por: Landry, Ishani, et al.
Publicado: (2022)

The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act
por: Moline, Margaret, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lpatakngli6r5od9rgotc322oh